Summary of practice points from the case.
| Tumor necrosis factor-α (TNF-α) inhibition is associated with an increased risk of tuberculosis (TB) reactivation |
| Pretreatment screening for latent tuberculosis infection (LTBI) substantially reduces but does not eliminate the risk of TB disease |
| Patients with a high risk of TB exposure may be considered for LTBI treatment even if screening tests are negative |
| Expert assessment of TB risk should be sought before commencement of TNF-α inhibition |